Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Embera NeuroTherapeutics

Embera NeuroTherapeutics
2007 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series B LATEST DEAL TYPE
$6.13M LATEST DEAL AMOUNT
12 INVESTORS
Description

Provider of addiction treatment medication designed to moderate activities in the stress response system. The company's medication potentially reduce the cravings and loss of control that drive addiction by uniquely targeting multiple pathways, to maximize potential efficacy more than either drug used alone, enabling people to abstain from smoking and drug use.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 29 Babe Ruth Drive
  • Suite 210
  • Sudbury, MA 01776
  • United States

+1 (978) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Embera NeuroTherapeutics’s full profile, request a free trial.

Embera NeuroTherapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series B) 02-Oct-2019 $6.13M 000.00 000.00 Completed Clinical Trials - Phase 2
9. Grant 26-Jul-2016 000.00 000.00 Completed Clinical Trials - Phase 1
8. Later Stage VC (Series B) 29-Jan-2016 00.00 000.00 0000 Completed Clinical Trials - Phase 1
7. Accelerator/Incubator 05-Aug-2015 0000 Completed Generating Revenue
6. Later Stage VC (Series A2) 26-Feb-2015 00.000 0000 000.00 Completed Generating Revenue
5. Grant 01-Jul-2014 00.00 00.00 Completed Generating Revenue
4. Early Stage VC (Series A2) 15-Aug-2011 00.00 00.00 00.000 Completed Startup
3. Early Stage VC (Series A) 03-Sep-2008 000 00.000 Completed Startup
2. Early Stage VC (Series A1) 25-Aug-2008 $1.36M $1.96M 0000 Completed Startup
1. Early Stage VC (Series A) 23-Jan-2007 $600K $600K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Embera NeuroTherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.00
Series A2 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A1 1,357,100 $0.001000 $0.06 $1 $1 1x $1 3.74%
To view this company’s complete Cap Table, request access »

Embera NeuroTherapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000000 07-Jul-2015 0000 00000 00000 Specialized Finance
To view this company’s complete investment and acquisition history, request access »

Embera NeuroTherapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Keiretsu Forum Venture Capital Minority 000 0000 000000 0
NO/LA Angel Network Angel Group Minority 000 0000 000000 0
Technomark Life Sciences Venture Capital Minority 000 0000 000000 0
Entrepreneurial Accelerator Program Accelerator/Incubator Minority 000 0000 000000 0
HRA Pharma PE-Backed Company Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Embera NeuroTherapeutics Executive Team (9)

Name Title Board
Seat
Contact
Info
Robert Linke Chief Executive Officer, Board Member & President
Gary Connor Director of Clinical Operations
Julie Straub Ph.D Vice President, CMC and Nonclinical Development
Ann Robbins Ph.D Vice President, Regulatory Affairs
Carol Gloff Ph.D Advisor, Development

3 Former Executives

You’re viewing 5 of 9 executives. Get the full list »

Embera NeuroTherapeutics Board Members (7)

Name Representing Role Since Contact
Info
Franz Hefti Ph.D Self Board Member 000 0000
John Beaird Self Board Member 000 0000
Joseph Lovett Louisiana Funds Board Member 000 0000
Robert Linke Embera NeuroTherapeutics Chief Executive Officer, Board Member & President 000 0000
Ross Barrett JD BVM Capital Chairman 000 0000

2 Former Board Members

You’re viewing 5 of 7 board members. Get the full list »